Back to search

Article

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomization

2021-08-09

Abstract excerpt

<h4>Background</h4> Large-scale molecular profiling and genotyping provide a unique opportunity to systematically compare the genetically predicted effects of therapeutic targets on the human metabolome. <h4>Methods</h4> We firstly constructed genetic risk scores for 8 drug targets on the basis that they primarily modify low-density lipoprotein (LDL) cholesterol (HMGCR, PCKS9 & NPC1L1), high-density lipoprotein (H...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
53677e23-c980-55b5-bbc5-ad27e6312155
DOI
10.1101/2021.08.06.21261699
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationDOI 10.1101/2021.08.06.21261699
Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.Semantic proximity
A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular diseaseSemantic proximity
Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity
Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity
Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity
Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity
Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity
Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.Semantic proximity
Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study.Semantic proximity
Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysisSemantic proximity
Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.Semantic proximity
Select a neighboring publication to make it the new centre.